Once considered fringe, psilocybin is now making serious waves in Silicon Valley, where microdosing has evolved from a quiet wellness hack into an openly discussed mental performance enhancer. A new Financial Times report highlights a surge in psilocybin usage among tech executives and startup founders in the Bay Area — many of whom view the compound as a tool for emotional regulation and creative problem-solving.
Unlike previous underground trends, today’s psilocybin movement is more structured. Spiritual retreats now openly cater to executives, and new startups are emerging to support microdosing regimens with precision dosing, psychological support, and digital integration. Companies like NeuraPath and SomaSync have begun building subscription-based services that combine low-dose psychedelic stacks with AI-driven mental health coaching.
Many proponents cite emerging studies — such as recent results from Johns Hopkins and NYU — showing that psilocybin can significantly reduce treatment-resistant depression and anxiety. But outside of clinical settings, professionals in non-medical fields are also touting the compound’s benefits. “I use it once a week. It lets me approach problem-solving with a completely fresh mindset,” said a senior engineer at a major tech firm who spoke anonymously.
Regulatory bodies have yet to catch up. While Oregon and Colorado have legalized certain psilocybin uses, federal legality remains a barrier. Still, the shift in narrative — from drug taboo to brain optimization — suggests that federal reconsideration may be on the horizon. Investors are already circling.
Source: Financial Times
